Peringatan Keamanan

An overdose of nitrazepam may lead to impaired breathing, dizziness, decreased cognition and balance, bluish nails and lips, slurred speech, and extreme somnolence, among others. In severe overdose, these symptoms may progress to a coma with a possibility of death.

Nitrazepam

DB01595

small molecule approved

Deskripsi

A benzodiazepine derivative used as an anticonvulsant and hypnotic.

Struktur Molekul 2D

Berat 281.2661
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 15-38 hours (mean elimination half life 26 hours).
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Bioavailability is 53-94% following oral administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol.
  • 2. Limit caffeine intake.
  • 3. Take with food.

Interaksi Obat

908 Data
Buprenorphine Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Hydrocodone Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Magnesium sulfate The therapeutic efficacy of Nitrazepam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Nitrazepam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Mirtazapine Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Orphenadrine Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Pramipexole Nitrazepam may increase the sedative activities of Pramipexole.
Ropinirole Nitrazepam may increase the sedative activities of Ropinirole.
Rotigotine Nitrazepam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Nitrazepam.
Suvorexant Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Thalidomide Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Clozapine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Clozapine.
Methadone Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Sodium oxybate Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Teduglutide The serum concentration of Nitrazepam can be increased when it is combined with Teduglutide.
Yohimbine The therapeutic efficacy of Nitrazepam can be increased when used in combination with Yohimbine.
Mefloquine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Nitrazepam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Nitrazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Flumazenil Flumazenil may decrease the sedative activities of Nitrazepam.
Rifampin The serum concentration of Nitrazepam can be decreased when it is combined with Rifampicin.
Tetracosactide The serum concentration of Nitrazepam can be increased when it is combined with Tetracosactide.
Ethanol Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Zimelidine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Nitrazepam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Sibutramine.
Escitalopram The risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Nitrazepam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Nitrazepam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Nitrazepam is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Nitrazepam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Nitrazepam.
Cocaine The risk or severity of methemoglobinemia can be increased when Nitrazepam is combined with Cocaine.
Nicardipine The metabolism of Nitrazepam can be decreased when combined with Nicardipine.
Quinidine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Quinidine.
Zopiclone The risk or severity of adverse effects can be increased when Nitrazepam is combined with Zopiclone.
Caffeine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Caffeine.
Dyphylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Dyphylline.
Pentoxifylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Pentoxifylline.
Mercaptopurine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mercaptopurine.
Oxtriphylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Oxtriphylline.
Theobromine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theobromine.
Fenethylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Fenethylline.
8-azaguanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 8-azaguanine.
7,9-Dimethylguanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 7,9-Dimethylguanine.
Xanthine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Xanthine.
7-Deazaguanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 7-Deazaguanine.
Guanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Guanine.
9-Methylguanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 9-Methylguanine.
Peldesine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Peldesine.
Hypoxanthine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Hypoxanthine.
9-Deazaguanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 9-Deazaguanine.
Propentofylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Propentofylline.
Valomaciclovir The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Valomaciclovir.
3-isobutyl-1-methyl-7H-xanthine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
Uric acid The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Uric acid.
Doxofylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Doxofylline.
6-O-benzylguanine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 6-O-benzylguanine.
Lisofylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Lisofylline.
Lobucavir The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Lobucavir.
Cafedrine The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Cafedrine.
Theodrenaline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theodrenaline.
Bamifylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Bamifylline.
Proxyphylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Proxyphylline.
Acefylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Acefylline.
Etamiphylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Etamiphylline.
Pentifylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Pentifylline.
Bufylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Bufylline.
Bromotheophylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Bromotheophylline.
Furafylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Furafylline.
8-chlorotheophylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with 8-chlorotheophylline.
PCS-499 The therapeutic efficacy of Nitrazepam can be decreased when used in combination with PCS-499.
Theophylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theophylline.
Aminophylline The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Aminophylline.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Nitrazepam.

Target Protein

Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1
GABA(A) Receptor GABRA1
GABA(A) Receptor Benzodiazepine Binding Site GABRA1
Sodium channel protein type 1 subunit alpha SCN1A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2883820
    Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41.
  • PMID: 7782744
    Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6.
  • PMID: 2570451
    Oelschlager H: Chemical and pharmacologic aspects of benzodiazepines. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72.
  • PMID: 10877119
    Podhorna J, Krsiak M: Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice. Behav Pharmacol. 2000 Apr;11(2):143-51.
  • PMID: 1676167
    Nowakowska E, Chodera A: Studies on the involvement of opioid mechanism in the locomotor effects of benzodiazepines in rats. Pharmacol Biochem Behav. 1991 Feb;38(2):265-6.

Contoh Produk & Brand

Produk: 10 • International brands: 37
Produk
  • Apo-nitrazepam
    Tablet • 5 mg • Oral • Canada • Generic • Approved
  • Apo-nitrazepam
    Tablet • 10 mg • Oral • Canada • Generic • Approved
  • Mogadon
    Tablet • 5 mg • Oral • Canada • Approved
  • Mogadon
    Tablet • 10 mg • Oral • Canada • Approved
  • Nitrazadon
    Tablet • 5 mg • Oral • Canada • Approved
  • Nitrazadon
    Tablet • 10 mg • Oral • Canada • Approved
  • Nitrazepam-10
    Tablet • 10 mg • Oral • Canada • Approved
  • Nitrazepam-5
    Tablet • 5 mg • Oral • Canada • Approved
Menampilkan 8 dari 10 produk.
International Brands
  • Alodorm
  • Apodorm
  • Arem
  • Atempol
  • Benzalin
  • Calsmin
  • Eatan
  • Eunoctin
  • Gerson
  • Hipnax

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul